Jayme Holmes

TL;DR: How the systematic collection and processing of a wide array of genomic, proteomic, chemical and disease-related resource data by the IDG Knowledge Management Center have enabled the development of evidence-based criteria for tracking the target development level (TDL) of human proteins is discussed.

TL;DR: Two resources developed by the IDG Knowledge Management Center are described: the Target Central Resource Database (TCRD) which collates many heterogeneous gene/protein datasets and Pharos (https://pharos.nih.gov), a multimodal web interface that presents the data from TCRD.

TL;DR: The integration with FDA drug labels enables text mining applications for drug adverse events and clinical trial information, and the overlap between DrugCentral FDA-approved drugs and their presence in four different chemical collections, are discussed.

TL;DR: The current release of DrugCentral includes 109 newly approved active pharmaceutical ingredients in the US, Europe, Japan and other countries; and two molecular entities of interest for COVID19, and incorporated REDIAL-2020, a machine learning platform that estimates anti-SARS-CoV-2 activities.

TL;DR: The following new data sources have been included: Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), FDA Orange Book information, L1000 gene perturbation profile distance/similarity matrices and estimated protonation constants.